Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity
NCT ID: NCT01180231
Last Updated: 2013-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
77 participants
INTERVENTIONAL
2010-09-30
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The prevalence of obesity and MS is also very high in children and young adults. While there are increasing numbers of studies assessing risk factors for cardiovascular and kidney disease in middle aged to older obese subjects, few studies have addressed the issue of the presence of obesity in young adults and its association with MS on early damage to the organs such as the kidneys, the heart and the blood vessels. The investigators' laboratory has a particular interest on the sympathetic nervous system, which is an important regulatory mechanism of both metabolic and cardiovascular function, as altered sympathetic activity may play a role in the complications of obesity.
Moxonidine is a medication that is approved in Australia by the Therapeutic Goods Administration to treat high blood pressure. It works by decreasing the activity of the sympathetic nervous system. With the elevation of the sympathetic activity in obesity, the investigators believe moxonidine may have a favourable role in rescuing early organ damage associated with obesity. This study will assess whether treating obese subjects with moxonidine have positive effects on blood vessels, cardiac and kidney function and anxiety disorder. The investigators will also examine the influence of the sympathetic nervous system activity in these possible altered cardiac, kidney and vessel functions.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Moxonidine
Moxonidine (Physiotens)
Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
Diet
Dietary intervention
Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
Moxonidine and diet
Subjects will be asked to take moxonidine and follow dietary plan designed by a qualified nutritionist for 6 months.
Moxonidine (Physiotens)
Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
Dietary intervention
Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
Control
Subjects will not be asked to take any interventions.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moxonidine (Physiotens)
Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
Dietary intervention
Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Abdominal obesity according to International Diabetes Federation (IDF) definition
Exclusion Criteria
* history of cardiovascular disease
* history of diabetes
* history of psychiatric illness
18 Years
30 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baker Heart and Diabetes Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
BakerIDI Heart and Diabetes Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BakerIDI Heart and Diabetes Institute
Prahran, Victoria, Australia
BakerIDI Heart and Diabetes Institute
Prahran, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Elisabeth Lambert, PhD
Role: primary
Carolina Sari, BSci (Hons.)
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Lambert EA, Sari CI, Eikelis N, Phillips SE, Grima M, Straznicky NE, Dixon JB, Esler M, Schlaich MP, Head GA, Lambert GW. Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies. Obesity (Silver Spring). 2017 Nov;25(11):1894-1902. doi: 10.1002/oby.21962. Epub 2017 Sep 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Project 168-10
Identifier Type: -
Identifier Source: org_study_id